Growth Metrics

Biogen (BIIB) Cash & Current Investments (2016 - 2025)

Biogen has reported Cash & Current Investments over the past 17 years, most recently at $3.8 billion for Q4 2025.

  • Quarterly results put Cash & Current Investments at $3.8 billion for Q4 2025, up 60.66% from a year ago — trailing twelve months through Dec 2025 was $3.8 billion (up 60.66% YoY), and the annual figure for FY2025 was $3.8 billion, up 60.66%.
  • Cash & Current Investments for Q4 2025 was $3.8 billion at Biogen, down from $4.0 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for BIIB hit a ceiling of $6.1 billion in Q2 2023 and a floor of $1.0 billion in Q4 2023.
  • Median Cash & Current Investments over the past 5 years was $3.0 billion (2021), compared with a mean of $3.3 billion.
  • Biggest five-year swings in Cash & Current Investments: plummeted 78.69% in 2024 and later surged 141.84% in 2025.
  • Biogen's Cash & Current Investments stood at $3.8 billion in 2021, then rose by 28.67% to $4.9 billion in 2022, then tumbled by 78.54% to $1.0 billion in 2023, then surged by 126.21% to $2.4 billion in 2024, then skyrocketed by 60.66% to $3.8 billion in 2025.
  • The last three reported values for Cash & Current Investments were $3.8 billion (Q4 2025), $4.0 billion (Q3 2025), and $2.8 billion (Q2 2025) per Business Quant data.